158 related articles for article (PubMed ID: 27111237)
1. Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.
Platt A; Xia Z; Liu Y; Chen G; Lazarus P
Pharmacogenet Genomics; 2016 Aug; 26(8):370-80. PubMed ID: 27111237
[TBL] [Abstract][Full Text] [Related]
2. In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17
Peterson A; Xia Z; Chen G; Lazarus P
Pharmacol Res Perspect; 2017 Jun; 5(3):e00314. PubMed ID: 28603633
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Cytosolic Glutathione
Teslenko I; Watson CJW; Xia Z; Chen G; Lazarus P
Drug Metab Dispos; 2021 Dec; 49(12):1047-1055. PubMed ID: 34593616
[TBL] [Abstract][Full Text] [Related]
4. Identification and Quantification of Novel Major Metabolites of the Steroidal Aromatase Inhibitor, Exemestane.
Luo S; Chen G; Truica CI; Baird CC; Xia Z; Lazarus P
Drug Metab Dispos; 2018 Dec; 46(12):1867-1878. PubMed ID: 30257855
[TBL] [Abstract][Full Text] [Related]
5. Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane.
Teslenko I; Trudeau J; Luo S; Watson CJW; Chen G; Truica CI; Lazarus P
J Pharmacol Exp Ther; 2022 Sep; 382(3):327-334. PubMed ID: 35793834
[TBL] [Abstract][Full Text] [Related]
6. Exemestane potency is unchanged by common nonsynonymous polymorphisms in CYP19A1: results of a novel anti-aromatase activity assay examining exemestane and its derivatives.
Peterson A; Xia Z; Chen G; Lazarus P
Pharmacol Res Perspect; 2017 Jun; 5(3):e00313. PubMed ID: 28603632
[TBL] [Abstract][Full Text] [Related]
7.
Teslenko I; Watson CJW; Chen G; Lazarus P
Mol Pharmacol; 2022 Aug; 102(5):216-22. PubMed ID: 35953090
[TBL] [Abstract][Full Text] [Related]
8. Role of the UGT2B17 deletion in exemestane pharmacogenetics.
Luo S; Chen G; Truica C; Baird CC; Leitzel K; Lazarus P
Pharmacogenomics J; 2018 Apr; 18(2):295-300. PubMed ID: 28534527
[TBL] [Abstract][Full Text] [Related]
9. Tibolone metabolism in human liver is catalyzed by 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four isoforms of the aldo-keto reductase (AKR)1C subfamily.
Steckelbroeck S; Oyesanmi B; Jin Y; Lee SH; Kloosterboer HJ; Penning TM
J Pharmacol Exp Ther; 2006 Mar; 316(3):1300-9. PubMed ID: 16339391
[TBL] [Abstract][Full Text] [Related]
10. The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man.
Malátková P; Havlíková L; Wsól V
Chem Biol Interact; 2014 Sep; 220():241-7. PubMed ID: 25063510
[TBL] [Abstract][Full Text] [Related]
11. Tibolone is metabolized by the 3alpha/3beta-hydroxysteroid dehydrogenase activities of the four human isozymes of the aldo-keto reductase 1C subfamily: inversion of stereospecificity with a delta5(10)-3-ketosteroid.
Steckelbroeck S; Jin Y; Oyesanmi B; Kloosterboer HJ; Penning TM
Mol Pharmacol; 2004 Dec; 66(6):1702-11. PubMed ID: 15383625
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin.
Bains OS; Grigliatti TA; Reid RE; Riggs KW
J Pharmacol Exp Ther; 2010 Dec; 335(3):533-45. PubMed ID: 20837989
[TBL] [Abstract][Full Text] [Related]
13. In vitro metabolism and identification of human enzymes involved in the metabolism of methylnaltrexone.
Tong Z; Chandrasekaran A; Li H; Rotshteyn Y; Erve JC; Demaio W; Talaat R; Hultin T; Scatina J
Drug Metab Dispos; 2010 May; 38(5):801-7. PubMed ID: 20173089
[TBL] [Abstract][Full Text] [Related]
14. A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma.
Corona G; Elia C; Casetta B; Diana C; Rosalen S; Bari M; Toffoli G
J Mass Spectrom; 2009 Jun; 44(6):920-8. PubMed ID: 19214962
[TBL] [Abstract][Full Text] [Related]
15. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol.
Breyer-Pfaff U; Nill K
J Pharm Pharmacol; 2004 Dec; 56(12):1601-6. PubMed ID: 15563768
[TBL] [Abstract][Full Text] [Related]
16. Validation of a rapid and sensitive LC-MS/MS method for determination of exemestane and its metabolites, 17β-hydroxyexemestane and 17β-hydroxyexemestane-17-O-β-D-glucuronide: application to human pharmacokinetics study.
Wang LZ; Goh SH; Wong AL; Thuya WL; Lau JY; Wan SC; Lee SC; Ho PC; Goh BC
PLoS One; 2015; 10(3):e0118553. PubMed ID: 25793887
[TBL] [Abstract][Full Text] [Related]
17. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
18. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases.
Rosemond MJ; St John-Williams L; Yamaguchi T; Fujishita T; Walsh JS
Chem Biol Interact; 2004 Mar; 147(2):129-39. PubMed ID: 15013815
[TBL] [Abstract][Full Text] [Related]
19. In vitro metabolism of fenofibric acid by carbonyl reducing enzymes.
Malátková P; Kanavi M; Nobilis M; Wsól V
Chem Biol Interact; 2016 Oct; 258():153-8. PubMed ID: 27599626
[TBL] [Abstract][Full Text] [Related]
20. Carbonyl reduction of warfarin: Identification and characterization of human warfarin reductases.
Malátková P; Sokolová S; Chocholoušová Havlíková L; Wsól V
Biochem Pharmacol; 2016 Jun; 109():83-90. PubMed ID: 27055738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
